Citi a buyer of Alexion into ALXN1210 launch despite compeititon

After her deep-dive into the paroxysmal nocturnal hemoglobinuria/myasthenia gravis competitive landscape indicated several players, Citi analyst Robyn Karnauskas says she remains a buyer of Alexion Pharmaceuticals into the 2019 launch of ALXN1210. Alexion management is aware of competition and pricing pressure and is “armed with a multi-pronged strategy to tackle both,” Karnauskas tells investors in a research note. The analyst says that while the company’s pipeline has expanded with recent acquisitions, the near-term focus continues to be on Soliris and ALXN1210. She reiterates a Buy rating on the shares with a $190 price target.
https://thefly.com/landingPageNews.php?id=2828271